How did acquisitions impact the company's financial performance in fiscal year 2000?

The company completed numerous acquisitions, which are accounted for using the pooling-of-interests or purchase method. These acquisitions drove revenue growth and market expansion. However, they also resulted in significant merger-related costs and integration expenses, which impacted reported net earnings. The company views these costs as investments in its long-term growth strategy.

What are the main drivers of revenue growth and what factors are impacting profitability?

Revenue growth in fiscal year 2000 was primarily driven by increased sales volume and pharmaceutical price increases within the Pharmaceutical Distribution and Provider Services segment, as well as strong performance in its specialty distribution businesses. Profitability, particularly gross margin, was slightly impacted by a shift towards a higher mix of lower-margin pharmaceutical distribution revenue and competitive pricing pressures in certain product lines. However, the company mitigated some of these impacts through cost control measures and operational efficiencies.

What is the company's financial health and outlook based on this filing?

Cardinal Health demonstrated strong revenue growth and maintained a healthy liquidity position with a substantial amount of working capital and available credit facilities. Despite merger-related costs impacting net income, the underlying business operations showed positive trends in revenue generation and expense management. The company's strategy of continued acquisitions and expansion into higher-margin service areas suggests a forward-looking approach aimed at sustained growth and market leadership in the healthcare industry.

CAH 10-K FY2000 Annual Report — Revenue, Net Income, EPS

Q: What is Cardinal Health's primary business focus and how has it evolved?

Cardinal Health operates as a leading provider of products and services to healthcare providers and manufacturers. Its core business segments include Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The company has significantly evolved through a strategy of aggressive acquisitions, expanding its offerings beyond traditional pharmaceutical distribution to include a comprehensive suite of healthcare solutions and services.

Summary

Cardinal Health, Inc.'s 2000 10-K filing reveals a company undergoing significant growth and diversification through a series of strategic acquisitions. The company operates across four key segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. Fiscal year 2000 saw substantial revenue growth, driven primarily by its pharmaceutical distribution business, with expanding services and product lines aimed at improving healthcare efficiency and quality. Despite strong revenue performance, the company experienced a slight decline in gross margins, largely attributed to a shift in revenue mix towards lower-margin pharmaceutical distribution. However, management has focused on cost controls and productivity gains, which have helped reduce selling, general, and administrative expenses as a percentage of revenue. The company also navigated a complex period of integration costs related to its numerous acquisitions, which impacted net earnings but were viewed as necessary investments for long-term expansion. Cardinal Health maintained a strong liquidity position and continued its aggressive acquisition strategy, signaling a commitment to further market consolidation and service expansion.

Key Highlights

1Significant revenue growth of 17% in fiscal year 2000, reaching $25.2 billion, driven by the Pharmaceutical Distribution and Provider Services segment.

2Continued aggressive acquisition strategy, with multiple mergers and acquisitions completed in the preceding years and subsequent to fiscal year-end, indicating a focus on market expansion and diversification.

3Operating across four distinct segments: Pharmaceutical Distribution, Medical-Surgical Products, Pharmaceutical Technologies, and Automation & Information Services, providing a broad range of healthcare solutions.

4Slight decrease in overall gross margin to 11.4% from 12.2% in the prior year, primarily due to a higher proportion of lower-margin pharmaceutical distribution revenue.

5Reduction in Selling, General, and Administrative (SG&A) expenses as a percentage of revenue to 6.5% from 7.3% in the prior year, reflecting cost control efforts and economies of scale.

6Incurrence of $64.7 million in merger-related costs during fiscal year 2000, impacting net earnings but reflecting the ongoing integration of acquired businesses.

7Strong liquidity position maintained, with working capital increasing and ample credit facilities available to support ongoing operations and growth initiatives.

Frequently Asked Questions